No additional risk of congenital anomalies after first-trimester dydrogesterone use: a systematic review & meta-analysis
This analysis reviews research data to assess whether using Dydrogesterone during the first trimester of pregnancy increases the risk of birth defects. The findings suggest that Dydrogesterone use in early pregnancy does not pose an additional risk for congenital anomalies compared to the general population.
2026-06-30
Read More
Dydrogesterone treatment for menstrual-cycle regularization in abnormal uterine bleeding ovulation dysfunction (AUB-O) patient
This study examines the use of Dydrogesterone, a progesterone-based medication, to regulate menstrual cycles in patients with abnormal uterine bleeding caused by ovulation disorders. The research evaluates the effectiveness of this treatment in normalizing menstrual function.
2026-06-30
Read More
The first isolation of multiple antifungal-drug-resistant Trichophyton rubrum in china and the novel resistance mechanism
This article shows an in-vitro antifungal susceptibility study analyzing multidrug-resistant (MDR) clinical isolates of Trichophyton rubrum. When compared against common systemic and topical agents like terbinafine, itraconazole, fluconazole, and voriconazole, luliconazole demonstrated exceptional potency with the lowest MIC (0.0005). The findings conclude that luliconazole is a rational, science-backed choice for managing difficult, resistant, and recurrent dermatophytosis cases.
2026-06-30
Read More
Once-daily luliconazole cream 1% for the treatment of interdigital tinea pedis
This article shows a randomized controlled trial evaluating a 14-day regimen of once-daily Luliconazole 1% cream in 322 patients with interdigital tinea pedis (athlete's foot). Compared to a vehicle cream, luliconazole achieved significantly higher complete clearance (14.0% vs 2.8%) and mycological cure (56.1% vs 27.1%) by Day 42. It concludes that the formulation is highly effective with a short course, well-tolerated, and serves as a preferred option to overcome non-compliance.
2026-06-30
Read More
Therapeutic efficacy of topically used luliconazole vs terbinafine 1% creams
This article shows a randomized controlled trial comparing Luliconazole 1% cream and Terbinafine 1% cream once daily for 14 days in patients with dermatophytosis caused by T. mentagrophytes. Luliconazole demonstrated a significantly lower MIC and a faster decline in fungal presence, reaching 72% clearance by Day 21. It concludes that its high potency and long-lasting effects make it ideal for treating recalcitrant dermatophytosis.
2026-06-30
Read More
Antifungal efficacy of luliconazole-loaded nanostructured lipid-carrier gel in an animal model of dermatophytosis
This article shows an in vivo experimental study using a guinea pig model infected with terbinafine-resistant Trichophyton indotineae. It highlights that traditional topical formulations suffer from poor solubility and penetration. In contrast, the newly evaluated luliconazole nanostructured lipid-carrier (LCZ-NLC 1%) gel achieved a 100% treatment efficacy by Day 21, markedly improving skin permeation and retention compared to standard LCZ 1% (70%) and Terbinafine 1% (40%).
2026-06-30
Read More
Luliconazole for the treatment of fungal infections: an evidence-based review
This article shows an evidence-based review focusing on clinical trials evaluating Luliconazole 1% cream for Tinea pedis and Tinea cruris. The data demonstrates that luliconazole requires a shorter treatment duration (7 days to 2 weeks) compared to conventional topical antifungals, while yielding 20–30% higher cure rates (e.g., 70% vs 50% for Tinea pedis against Bifonazole 1%). It concludes that its potent fungicidal activity improves patient adherence and offers a reliable solution for recurrent and resistant infections.
2026-06-30
Read More
A critical appraisal of once-daily topical luliconazole for the treatment of superficial fungal infections
This article shows a comprehensive overview of Phase II/III randomized controlled trials (RCTs) evaluating Luliconazole 1% cream once daily against multiple comparators (including terbinafine, clotrimazole, and bifonazole) for a duration of 1 to 2 weeks. Key findings indicate a high clinical and mycological cure rate of up to ~88%, lower Minimum Inhibitory Concentrations (MICs) than comparators against common pathogens like T. rubrum, and significantly higher efficacy in treating Tinea cruris compared to a vehicle alone. It concludes that luliconazole is highly effective, fast-acting, and well-tolerated.
2026-06-30
Read More
A Comparative Observational Study of Dual Therapy Itopride & Esomeprazole vs Monotherapy Esomeprazole in Gastroesophageal Reflux Disease
This article builds the case that a subset of GERD patients have persistent symptoms despite effective acid suppression, implying motility-related pathophysiology that PPIs alone don't address. Itopride's dual D2-antagonist/cholinesterase-inhibitor mechanism is proposed to enhance gastric motility and emptying and potentially improve LES tone and esophageal clearance, prompting a comparison of itopride + esomeprazole against esomeprazole alone. Study design: a prospective, comparative observational study of 150 GERD patients in India over 6 months, comparing itopride 50 mg + esomeprazole 40 mg (dual therapy) against esomeprazole 40 mg monotherapy. Symptom relief was assessed via the FSSG (Frequency Scale for the Symptoms of GERD) score at 4 weeks: 66% relief with dual therapy versus 47% with monotherapy (p=0.0101).
2026-06-30
Read More
Proposed Algorithm for the Diagnosis and Management of Diabetic Gastroparesis in the Indian Clinical Setting
This article lays out diabetic gastroparesis as a complication of long-standing diabetes — delayed gastric emptying driving nausea, vomiting, early satiety, bloating, and postprandial discomfort — and frames diagnosis as challenging because of overlapping symptom profiles and variable presentation. Itopride is positioned as supporting gastroduodenal motility, accelerating gastric emptying, and offering a favorable CNS/cardiac safety profile. The algorithm itself: a patient with nausea, vomiting, dyspepsia, or anorexia on a background of long-standing diabetes undergoes history, exam, and initial investigations, leading to suspected gastroparesis, with medication-induced causes ruled out first. Endoscopy then excludes mechanical gastric outflow obstruction (if found, that's treated directly). If endoscopy is normal, a gastric emptying test distinguishes confirmed delayed emptying — true diabetic gastroparesis, fed into the management pathway below — from a normal result, which gets reclassified as functional dyspepsia rather than gastroparesis. Confirmed gastroparesis then follows stepwise escalation: first glycemic control + diet/lifestyle modification + prokinetics (with or without antiemetics); if inadequate, switch prokinetic or add a neuromodulator; if still inadequate, enteral nutrition; and if that fails, endoscopic therapy or surgery.
2026-06-30
Read More
Effect of Itopride on Esophageal Motility and Lower Esophageal Sphincter Function in Man
This Belgian crossover study targets a different reflux mechanism — transient lower esophageal sphincter relaxations (TLESRs), the main driver of reflux episodes that acid suppression doesn't address. Twelve healthy volunteers received itopride 50/100 mg TID (3-day pretreatment) versus placebo in a randomized, crossover, placebo-controlled manometry study. Itopride significantly reduced postprandial TLESRs (roughly 6 with placebo down to about 3 with itopride; p=0.04) without affecting baseline LES pressure or peristalsis, supporting a mechanism-based rationale for itopride in GERD beyond simple prokinetic gastric emptying.
2026-06-30
Read More
Proposed Algorithm for the Diagnosis and Management of Functional Dyspepsia–Gastroesophageal Reflux Disease Overlap in the Indian Clinical Setting
This is an expert-consensus flowchart, not a trial, for working up chronic reflux/dyspeptic symptoms. After history, exam, and initial investigations (including USG), patients are triaged by alarm symptoms. Those without alarm symptoms enter an empirical pathway — a 4-week trial of prokinetic + PPI for suspected FD-GERD overlap, with non-responders escalated to double-dose PPI and then to esophageal manometry and 24-hour pH-impedance monitoring to objectively confirm overlap (abnormal acid exposure ? combine PPI + prokinetic; normal study ? gastric scintigraphy/EGG or add a neuromodulator). Those with alarm symptoms go straight to endoscopy and H. pylori testing, with organic causes treated directly and H. pylori-positive patients undergoing eradication and retesting. The conclusion positions itopride as the consensus-endorsed prokinetic within this algorithm on the basis of its dual mechanism and low cardiac/CNS adverse-effect profile.
2026-06-30
Read More
A Placebo-Controlled Trial of Itopride in Functional Dyspepsia
This is the Holtmann et al. NEJM (2006) trial — a multicenter, randomized, double-blind, placebo-controlled study in Germany (n=554 FD patients) testing itopride 50/100/200 mg TID against placebo over 8 weeks. Global symptom response was higher with itopride (56.7–64.4% across doses) versus 41.7% with placebo, with safety comparable to placebo and no cardiac signal. Worth knowing as context: this trial, though well-designed and the most frequently cited positive itopride study, turned out to be something of an outlier. Two larger confirmatory Phase III trials run afterward (one North American, one international) found itopride's response rate barely differed from placebo's on the primary global assessment endpoint — roughly 45% vs 46% in one trial and 38% vs 35% in the other — leading the authors to conclude itopride showed no meaningful symptom advantage over placebo in that population. Axcan Pharma halted itopride's development for functional dyspepsia in September 2006 after both of those Phase III trials failed to show significant improvement on the co-primary pain and fullness endpoints, and itopride has never been FDA-approved in the US, though it remains marketed across Japan, parts of Europe, and Asia. This episode is well-known enough in GI trial-design literature to have its own retrospective commentary piece. None of this invalidates itopride's use elsewhere (the meta-analytic evidence on page 11 still shows modest benefit), but it's useful to know that the headline trial in this slide is the positive outlier rather than the confirmed result.
2026-06-30
Read More
Efficacy and Safety of Pantoprazole and Itopride in Patients with Overlap of GERD and Dyspepsia: A Prospective, Open-Label, Single-Arm Pilot Study
This single-center pilot trial targets the substantial overlap between GERD and dyspepsia (up to 41.5% of GERD patients have overlapping dyspepsia, and ~40% are partially or fully refractory to standard PPI therapy), on the premise that PPI monotherapy doesn't correct underlying motility or LES dysfunction. Fifty adults with ?3 months of GERD received a fixed-dose combination of pantoprazole 40 mg + itopride 150 mg daily for 6 weeks, tracked via the validated GSAS distress scoring system. GSAS overall distress score fell from 2.6 to 0.4 (P<0.001), heartburn frequency dropped from 84.0% to 26.8%, and symptom duration fell from 79.3 hours to essentially zero, with improvement evident from week 2 onward and good tolerability in >97% of patients. Worth flagging: this is a small (n=50), open-label, single-arm design with no placebo or comparator arm, so the improvement can't be separated from natural symptom fluctuation or placebo response — a real limitation given how variable GERD/dyspepsia symptoms can be week to week.
2026-06-30
Read More
A Prokinetic Agent with Dual Effects: Itopride in the Treatment of Dysmotility
This article summarizes a meta-analysis of 9 RCTs (n=2,620 adults with functional dyspepsia) evaluating itopride's efficacy and safety. It notes that functional dyspepsia accounts for ~60% of dyspeptic presentations, with delayed gastric emptying in ~30% of cases, and that many existing prokinetics are limited by QT prolongation or CNS effects. Itopride 50 mg TID was compared against placebo, domperidone, and mosapride across multinational, multicenter trials. Key findings: significant improvement in postprandial fullness (p=0.02) and early satiety (p=0.04), QoL score improvement of 18.0 vs. 13.2 for placebo, and superior efficacy relative to the comparator drugs. The conclusion attributes this to itopride's dual mechanism — D2 receptor antagonism plus acetylcholinesterase inhibition — while noting it doesn't cross the blood-brain barrier or prolong QT, giving tolerability comparable to placebo.
2026-06-30
Read More
Role of Itopride in Minimizing Post-Prandial Glucose Excursion in Type 2 Diabetic Patients
This ar a comparative interventional study testing whether adding itopride to standard oral anti-diabetic (OAD) therapy reduces post-prandial glucose (PPG) excursion in type 2 diabetics with symptoms of delayed gastric emptying (nausea, bloating, early satiety). The rationale is that diabetic autonomic neuropathy causes delayed gastric emptying, which impairs incretin response and early insulin secretion — a mechanism conventional OADs don't target. Over 1 year, 100 patients were split into Group I (OAD + placebo, n=50) and Group II (OAD + itopride, n=50). Mean PPG excursion fell from 176.56 mg/dL in controls to 62.52 mg/dL with itopride. The conclusion frames itopride as a rational adjunct in T2DM patients with delayed gastric emptying and suboptimal post-prandial control, working by improving gastric motility and incretin-mediated insulin secretion.
2026-06-30
Read More
Comparison of the Gastrointestinal Prokinetic Effects of Itopride and Metoclopramide
In this study: Itopride produced stronger prokinetic activity across the fundus, pylorus, jejunum, and colon compared with metoclopramide. Showed a favorable ED50 profile, indicating effective enhancement of both upper and lower gastrointestinal motility. Unlike metoclopramide, it does not cross the blood–brain barrier, suggesting a lower risk of CNS and extrapyramidal adverse effects.
2026-06-30
Read More
Comparison of Itopride plus Rabeprazole versus Domperidone plus Rabeprazole in Patients with Gastroesophageal Reflux Disease (GERD)
In this study: Itopride 50 mg TID + rabeprazole 20 mg OD showed numerically higher symptom relief compared with domperidone + rabeprazole. Demonstrated better endoscopic healing, indicating improved control of reflux-related mucosal damage. Consistent improvement across follow-up visits with good tolerability, supporting itopride as a preferred prokinetic in GERD.
2026-06-30
Read More
Efficacy of Itopride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
In this study: Itopride significantly reduced diarrhea, abdominal pain, and abdominal distension in IBS-D patients. Showed significant improvement in Quality of Life (QoL) parameters (P < 0.05). Marked improvement was seen in physiological function, social function, and bodily pain. Provided faster recovery with better overall symptom relief compared to baseline.
2026-06-30
Read More
Effect of Itopride on Gastric Emptying and Glycemic Control in Patients with Diabetic Gastroparesis
In this study: Itopride improved gastric motility and provided rapid relief from bloating, nausea, and postprandial fullness in diabetic gastroparesis. Enabled faster recovery with better overall symptom control. Also improved glycemic control with significant reductions in HbA1c, fasting plasma glucose, and postprandial glucose.
2026-06-30
Read More
Effect of itopride on longstanding diabetes mellitus
This article discusses about the effect of itopride on longstanding diabetes mellitus
2026-06-30
Read More
Itopride: Clinical Applications and Outcomes in Gastrointestinal Motility Disorders
This article discusses the clinical applications of itopride in gastrointestinal motility disorders, summarizing evidence on symptom improvement, enhancement of gastric motility, treatment outcomes, and safety across different patient populations.
2026-06-30
Read More
Itopride for Functional Gastrointestinal Disorders: Clinical Evidence and Therapeutic Benefits
This article reviews clinical evidence supporting the use of itopride in functional gastrointestinal disorders, focusing on its efficacy in relieving dyspeptic symptoms, improving gastrointestinal motility, and enhancing patient-reported outcomes with good tolerability.
2026-06-30
Read More
Clinical Efficacy and Safety of Itopride in Functional Dyspepsia and Diabetic Gastroparesis: Evidence from Clinical Studies
This article summarizes evidence from randomized controlled trials, meta-analyses, observational studies, and post-marketing surveillance evaluating itopride in functional dyspepsia and diabetic gastroparesis. The evidence demonstrates significant improvement in postprandial fullness, early satiety, epigastric symptoms, gastric emptying, and overall symptom scores, while maintaining a favorable safety profile with minimal serious adverse events and no clinically significant QT interval prolongation.
2026-06-30
Read More
Itopride in the Management of Upper Gastrointestinal Motility Disorders
This article reviews the role of itopride in the management of upper gastrointestinal motility disorders, highlighting its dual mechanism of action, improvement of gastrointestinal motility, symptom relief, and favorable tolerability profile across patients with functional gastrointestinal disorders.
2026-06-30
Read MoreTherapeutic Effectiveness of Faropenem Against Major Bacterial Pathogens
This article summarizes the in vitro antibacterial activity of faropenem against clinically important pathogens responsible for respiratory, urinary, skin and soft tissue, and gynecological infections. It also outlines recommended dosing across different infectious conditions and emphasizes its broad antimicrobial coverage against common bacterial pathogens.
2026-06-30
Read More
Faropenem: Broad-Spectrum Activity, ?-Lactamase Stability, and Clinical Evidence in Acute Bacterial Infections
This article reviews the microbiological spectrum and clinical evidence supporting faropenem. It highlights its stability against ?-lactamases, activity against Gram-positive, Gram-negative, and anaerobic pathogens, including ESBL-producing organisms, and summarizes clinical studies demonstrating efficacy in acute bacterial sinusitis and uncomplicated cystitis. The evidence suggests that faropenem is an effective oral therapeutic option for selected bacterial infections, particularly when antimicrobial resistance is a concern.
2026-06-30
Read More
Clinical Efficacy of Faropenem in Different Infectious Diseases: Evidence Across Therapeutic Areas
This article summarizes the reported clinical efficacy of faropenem across multiple infectious diseases, including respiratory tract infections, urinary tract infections, gynecological infections, skin and soft tissue infections, surgical infections, dental infections, and otorhinolaryngological infections. It presents disease-specific clinical response rates from published studies, demonstrating consistently high efficacy in a broad range of bacterial infections.
2026-06-30
Read More
Effects of dienogest therapy on endometriosis related dysmenorrhea, dyspareunia, and endometrioma size
This study has evaluated the short-term (6-month) e cacy of 2 mg/day dienogest on reducingendometrioma size and alleviating dysmenorrhea and dyspareunia in patients with endometriosis
2026-06-30
Read More
Efficacy of dienogest in adolescent endometriosis: A narrative review
This narrative review summarizes the evidence supporting the efficacy and safety of dienogest in adolescent endometriosis.
2026-06-29
Read More
Comparison of the efficacy of dienogest and gnrh-analogue after endometriosis surgery
To compare the efficacy of dienogest and GnRH-analogue after endometriosis surgery.
2026-06-29
Read More
Short-term use of GnRH antagonist for severe pain in endometriosis
This study examines the short-term use of GnRH antagonist medications to relieve severe pain associated with endometriosis. The research evaluates how this hormone-based treatment can provide pain relief for patients with severe endometriosis symptoms.
2026-06-29
Read More
The potential role of elagolix for treating uterine bleeding associated to uterine myomas
This study explores how Elagolix may be used to treat heavy uterine bleeding caused by uterine fibroids (myomas). The research investigates the medication's effectiveness as a therapeutic option for managing fibroid-related bleeding.
2026-06-29
Read More
Treatment of endometriosis-associated pain with elagolix, an oral gnrh antagonist
This study evaluates how Elagolix, an oral GnRH antagonist medication, effectively treats pain caused by endometriosis. The research demonstrates the drug's mechanism and benefits in managing endometriosis-related pain symptoms.
2026-06-29
Read More
Endometriosis-related pain reduction during bleeding and nonbleeding days in women treated with elagolix
This study examines how elagolix medication reduces pain associated with endometriosis in women, comparing pain relief on days with and without menstrual bleeding. The research evaluates the drug's effectiveness in managing endometriosis symptoms throughout the menstrual cycle.
2026-06-29
Read More
Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review & meta-analysis
This is an analysis examining the effectiveness of Elagolix medication in reducing heavy menstrual bleeding caused by uterine fibroids in women. The study reviews and compares data from multiple clinical trials to assess treatment outcomes.
2026-06-29
Read More
Efficacy of monotherapy letrozole versus methotrexate for the management of ectopic pregnancy: a systematic review and meta-analysis of comparative studies
This study compares the effectiveness of Letrozole and Methotrexate as single-drug treatments for managing ectopic pregnancies. The analysis synthesizes evidence from multiple clinical trials to determine which medication produces better outcomes.
2026-06-29
Read More
Effect of letrozole doses on clinical pregnancy rates in polycystic ovary syndrome: a systematic review and network meta-analysis
This is a comprehensive analysis comparing different doses of Letrozole and their impact on pregnancy success rates in women with PCOS. The study synthesizes data from multiple research trials to determine the most effective dosing strategy.
2026-06-29
Read More
Letrozole for female infertility
This is an overview of letrozole's use as a medication to treat infertility in women.
2026-06-29
Read More
Co-treatment with letrozole during ovarian stimulation for IVF/ICSI: a systematic review and meta-analysis
This is a comprehensive analysis of research studies examining whether using Letrozole alongside standard fertility hormone treatments in IVF/ICSI procedures improves outcomes.
2026-06-29
Read More
Ovulation Induction Using Sequential Letrozole / Gonadotrophin in Infertile Women With PCOS: A Randomized Controlled Trial
This reviews a clinical trial comparing a two-step fertility treatment approach combining Letrozole and Gonadotrophin for women with PCOS to improve pregnancy outcomes.
2026-06-29
Read More
Ovarian response can be predicted in women with PCOS who have ovulation induction with Letrozole
This title refers to a medical research finding that demonstrates the ability to forecast how women with Polycystic Ovary Syndrome (PCOS) will respond to ovulation induction treatment using the medication Letrozole. The study suggests that predictive markers or parameters can be identified before or during treatment to anticipate ovarian response outcomes in this patient population. This has important clinical implications for fertility treatment planning and personalizing ovulation induction protocols for women with PCOS.
2026-06-29
Read More
Research progress of dydrogesterone in the treatment of endometriosis
This review summarizes the evolving evidence on the use of dydrogesterone in endometriosis, highlighting its effectiveness in relieving pain, suppressing disease progression, and preserving fertility. It supports dydrogesterone as a safe and well-tolerated option for long-term management of endometriosis.
2026-06-29
Read More
A comparative study of norethisterone and dydrogesterone in the treatment of heavy menstrual bleeding
This comparative study evaluates the efficacy and tolerability of dydrogesterone versus norethisterone in women with heavy menstrual bleeding. The findings suggest that dydrogesterone effectively reduces menstrual blood loss while offering a favorable safety and tolerability profile.
2026-06-29
Read More
In vitro activity of oral Faropenem against ESBL-producing Escherichia coli and Klebsiella pneumoniae
In this study, the antimicrobial activity of oral faropenem was evaluated against extended-spectrum ?-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae. The findings showed substantial in vitro susceptibility, suggesting that faropenem may be a useful oral therapeutic option for infections caused by these resistant Enterobacterales.
2026-06-29
Read More
Activity of Faropenem against multidrug-resistant Gram-positive clinical isolates
In this study, the antimicrobial efficacy of faropenem was investigated against multidrug-resistant Gram-positive organisms obtained from clinical isolates. The results demonstrated potent in vitro activity, including against resistant pathogens, supporting its potential use for difficult-to-treat Gram-positive infections
2026-06-29
Read More
Rapid inhibition of bacterial biofilm formation by Faropenem in respiratory tract pathogens
In this article, the effect of faropenem on bacterial biofilm formation was assessed. The results suggest that faropenem rapidly inhibited biofilm development, which may help reduce bacterial persistence and improve treatment outcomes in respiratory tract infections.
2026-06-29
Read More
Clinical role of dydrogesterone in reducing endometriosis-associated pelvic pain, improving lesion and quality-of-life parameters
This review highlights the clinical efficacy of dydrogesterone in alleviating endometriosis-associated pelvic pain, reducing lesion progression, and improving quality of life. It supports dydrogesterone as a well-tolerated long-term therapeutic option for women with endometriosis.
2026-06-29
Read More
In vitro antibacterial activity of Faropenem against respiratory tract pathogens
In this study, the antibacterial activity of faropenem was evaluated against common respiratory tract pathogens. The findings indicate that faropenem demonstrated broad-spectrum activity and favorable susceptibility against important respiratory bacteria, supporting its potential role in respiratory tract infections.
2026-06-29
Read More
Benefit of dydrogesterone loading dose (40 mg stat, followed by 10 mg BID) in threatened abortion and the pregnancy outcome
This study evaluates the efficacy of a dydrogesterone loading-dose regimen (40 mg stat followed by 10 mg twice daily) in women with threatened abortion. The findings suggest that early initiation of this regimen may improve pregnancy continuation and enhance overall pregnancy outcomes.
2026-06-29
Read More
Experience of Faropenem for the Management of Urinary Tract Infection
In this study, a real-world cross-sectional survey of 391 Indian urologists evaluated the clinical experience of using oral faropenem for complicated urinary tract infections (cUTIs). The survey found that all respondents considered faropenem effective, with many supporting its use as step-down therapy. It was also regarded as safe and well tolerated, with strong activity against ESBL-producing and other cephalosporin-resistant pathogens, supporting its role in the management of complicated UTIs.
2026-06-29
Read More
Analysis of the Practice of Switching Antibiotics from Intravenous to Oral Therapy at a Tertiary Care Hospital in Nepal: A Prospective Observational Study
In this study, a prospective observational study evaluated the implementation of intravenous-to-oral antibiotic switching in hospitalized patients. The findings revealed that although most patients were eligible for early conversion, only a small proportion were switched, highlighting the need for structured switch protocols. Early conversion reduced intravenous antibiotic duration and hospital stay, while oral faropenem was identified as a suitable step-down therapy because of its high oral bioavailability, broad-spectrum activity, and favorable safety profile.
2026-06-29
Read More
The addition of dydrogesterone improves pregnancy outcome in women with low progesterone levels receiving vaginal progesterone alone as luteal support in HRT-FET cycles
This study demonstrates that adding oral dydrogesterone to vaginal progesterone for luteal phase support improves pregnancy outcomes in women with low serum progesterone undergoing HRT-FET cycles. The findings support individualized luteal support to optimize implantation and ongoing pregnancy rates.
2026-06-29
Read More
Comparative In Vitro Activity of Faropenem Against Staphylococci
In this study, the in vitro antimicrobial activity of faropenem was compared with commonly used antibiotics against Staphylococcus species. The findings demonstrated potent activity, low minimum inhibitory concentrations (MICs), and sustained bactericidal effects, indicating strong effectiveness against susceptible staphylococcal isolates.
2026-06-29
Read More
Faropenem for the Management of Infectious Diseases: A Systematic Review of In Vitro Susceptibility Tests and Clinical Studies
In this article, a systematic review examined in vitro susceptibility data and clinical studies to assess the antimicrobial activity, resistance profile, and clinical efficacy of faropenem. The review found broad-spectrum activity, low MIC values against key pathogens, and clinical outcomes comparable or superior to commonly used oral antibiotics, supporting its role in community-acquired respiratory and urinary tract infections.
2026-06-29
Read More
Faropenem: A Stable and Orally Bioavailable ?-Lactam for Counteracting Resistant Pathogens and Infectious Diseases
In this article, published evidence on faropenem's antibacterial spectrum, ?-lactamase stability, and clinical utility was reviewed. The article highlights its broad-spectrum activity against resistant Gram-positive and Gram-negative pathogens and discusses its role as an effective oral option for managing common bacterial infections.
2026-06-29
Read More
The role of dydrogesterone in the prevention of pre-eclampsia
This review explores the potential role of dydrogesterone in reducing the risk of preeclampsia through its immunomodulatory and placental protective effects. It summarizes current evidence supporting the use of progesterone therapy in improving pregnancy outcomes among women at increased risk of preeclampsia.
2026-06-29
Read More
Efficacy and Safety of Faropenem in a Post-Marketing Surveillance Study
In this study, a large post-marketing surveillance analysis evaluated the effectiveness and safety of oral faropenem in routine clinical practice. The findings showed high clinical effectiveness across approved indications with an overall efficacy of approximately 95%, while adverse drug reactions were uncommon, supporting a favorable safety profile.
2026-06-29
Read More
Clinical Efficacy of Faropenem in Obstetric and Gynecological Infections
In this study, a multicenter prospective clinical trial evaluated the efficacy, bacteriological response, and safety of oral faropenem in 165 patients with mild-to-moderate obstetric and gynecological infections. The study reported high clinical and bacteriological success rates across various infections, with no significant adverse effects or laboratory abnormalities observed.
2026-06-29
Read More
A comparative, RCT in patients of pv bleeding comparing efficacy of oral Dydrogesterone vs vaginal progesterone in successful pregnancy outcome for patients with RPL
It overviews a comparison of the effi cacy of oral Dydrogesterone (30 mg/day) vs vaginal progesterone (600 mg/day) in maintaining pregnancy in women with recurrent pregnancy loss (RPL) presenting with first-trimester vaginal bleeding.
2026-06-29
Read More
Therapeutic effect of mirogabalin on peripheral neuropathic pain due to lumbar spine disease
This study evaluates the effectiveness of mirogabalin in patients with peripheral neuropathic pain associated with lumbar spine disease. The study reports significant improvements in pain severity, neuropathic symptoms, and functional outcomes after treatment. The article concludes that mirogabalin is an effective and well-tolerated treatment option for neuropathic pain related to lumbar spine disorders.
2026-06-29
Read More
Mirogabalin for central neuropathic pain following spinal cord injury
This article highlights the role of mirogabalin in the management of central neuropathic pain following spinal cord injury. It summarizes evidence demonstrating significant reductions in pain intensity, improvements in sleep disturbance and quality of life, and sustained analgesic efficacy throughout treatment. The article also discusses the favorable safety and tolerability profile of mirogabalin, supporting its use as an effective therapeutic option for central neuropathic pain.
2026-06-29
Read More
Mirogabalin as a therapeutic option for neuropathic pain emerging post-endodontic treatment: an observational study
This observational study investigates the effectiveness of mirogabalin in managing neuropathic pain following endodontic treatment. The study found significant reductions in pain intensity and improved patient outcomes during follow-up. The accompanying article further reviews the pharmacology, clinical efficacy, dosing recommendations, and safety profile of mirogabalin for the management of neuropathic pain.
2026-06-29
Read More
Mirogabalin: A novel selective ?2? calcium channel ligand for effective neuropathic pain management
This article focuses on the pharmacological characteristics of mirogabalin, emphasizing its selective receptor binding and sustained analgesic activity in neuropathic pain. It reviews evidence from clinical studies supporting its efficacy across various neuropathic pain conditions while maintaining favorable tolerability. The article also summarizes its mechanism of action, pharmacokinetics, dosing recommendations, and adverse event profile.
2026-06-29
Read More
Mirogabalin: The next generation gabapentinoid for neuropathic pain
This article discusses the pharmacological profile of mirogabalin and compares it with conventional gabapentinoids such as pregabalin and gabapentin. It highlights mirogabalin's higher selectivity and prolonged binding to the ?2?-1 calcium channel subunit, which may contribute to improved analgesic efficacy with fewer central nervous system adverse effects. The article also summarizes its mechanism of action, pharmacokinetics, clinical efficacy, dosing recommendations, and safety profile.
2026-06-29
Read More
Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo-controlled phase III study in Asian patients
This Phase III study evaluates the efficacy and safety of mirogabalin in patients with diabetic peripheral neuropathic pain (DPNP). The study demonstrated that mirogabalin significantly reduced pain compared with placebo, with improvement observed as early as the first week and sustained throughout the treatment period. The article also reports an acceptable safety profile with relatively low discontinuation rates due to adverse events.
2026-06-29
Read More
Dienogest versus norethisterone acetate in management of endometrial hyperplasia without atypia
This is an overview of a prospective controlled study that compares the effectiveness of dienogest and norethisterone acetate regimens in the treatment of endometrial hyperplasia without atypia.
2026-06-29
Read More
Efficacy and safety of 48 week low dose dienogest treatment in patients with endometriosis associated dysmenorrhea: a randomized, open label, parallel group trial
This is an randomized controlled trial that has evaluated the efficacy and safety of 1 mg versus 2 mg dienogest over 48 weeks in women with endometriosis-associated dysmenorrhea.
2026-06-29
Read More
Endometriosis is chronic disease, demanding a treatment that is proven with long-term safety
Endometriosis is a chronic, progressive disease that requires long-term management. Dienogest provides sustained symptom relief with a favorable safety profile, making it a suitable option for prolonged therapy while preserving fertility.
2026-06-29
Read More
Clinical efficacy of dienogest in endometriomas with diameter >4cm
This is an overview of a prospective observational study demonstrating the clinical efficacy of Dienogest in endometriomas with diameter >4cm
2026-06-29
Read More